Vygon Corporation receives Health Canada approval to commercialize Stiletto™ extended-dwell catheters

New generation catheters integrating SlipStream™ technology and patented insertion system now available to healthcare professionals in Canada, reinforcing Vygon's extensive range in vascular access devices

Lansdale, PA, USA, June 17, 2026 – Vygon Corporation, a leading group specialized in the design, manufacturing and marketing of medical devices in neonatology and vascular management clinical specialties, today announces that Stiletto™, its new generation of extended-dwell catheters integrating SlipStream™ technology, has received approval for commercialization from the federal institution Health Canada.

This approval supports Vygon's plans to accelerate its growth in North America, where extended-dwell catheters represent a significant, rapidly expanding segment of the vascular access market. Vygon has also appointed NIPRO Canada as a distributor for the entire country.

The Stiletto Extended Dwell Catheter (EDC) is a sterile, single-use medical device designed to allow healthcare professionals to sample blood and/or administer fluids over a short duration (<28 days) through a peripherally inserted catheter. It is manufactured in the US under the strict quality control standards consistent with international medical device regulations, with verified sterilization processes to ensure its safety for patient use.

Stiletto's patented insertion system, SlipStream, replaces the traditional Seldinger technique for EDCs. By eliminating guidewires and reducing procedural steps, SlipStream offers clinicians a simpler, safer and more intuitive technique, while delivering significant clinical benefits for patients.

"This approval reflects our strong commitment to supporting Canadian healthcare professionals with high-quality, innovative medical devices," said Peter Ciriello, USA chief executive officer at Vygon Corporation, in charge of the North American market. "Stiletto's SlipStream technology presents clinicians with a simpler, safer and more intuitive technique for inserting extended-dwell catheters, delivering significant improvements in patient comfort, safety and care efficiency, fully aligned with Vygon's mission to Value Life."

The global market for midline and extended-dwell catheter solutions is estimated at more than $3 billion, with an expected CAGR of between 6% and 9%. In 2024, North America dominated the midline catheters market with the largest revenue share, at 40.31%. The extended-dwell catheter segment is particularly dynamic, driven by the growing need for mid-term venous access solutions that combine clinical efficiency, safety and cost-effectiveness, especially in patients requiring long-term antibiotic therapy, fluid administration or chemotherapy.

Stiletto is Vygon's first entry into the extended-dwell catheter market. As a result, the company now offers one of the most comprehensive vascular access portfolios worldwide, covering a full continuum of solutions, including standard midlines, extended-dwell catheters, PICC lines, central venous catheters (CVC), implantable ports, and neonatal and pediatric vascular access devices.

Vygon will be showcasing Stiletto at the 40th Annual AVA (Association for Vascular Access) Scientific Meeting at the Gaylord Texan Resort & Convention Center, Grapevine, Texas, USA, October 2 - 4, 2026. The company also plans on attending many local AVA chapter meetings.

About Vygon

Vygon designs, manufactures and markets single-use medical devices and active medical devices for healthcare professionals in hospitals and for private and independent practitioners. A world leader in the neonatology and vascular management clinical specialties, the company also offers a wide range of products in hemodynamic management, adult enteral nutrition, airways management and loco-regional anesthesia. Vygon combines local and international in-depth expertise and know-how in each individual field.

With expertise across the entire value chain, from product design to the delivery of training for medical personnel, Vygon provides healthcare professionals with effective and innovative products tailored to their needs and those of their patients, for optimal use and safety.

Through its network of 26 subsidiaries and 400 distributors, Vygon distributes over 205 million products a year in more than 120 countries. Its products display the CE and/or FDA mark and are manufactured in the group's eleven factories in Europe, the US and Colombia.

Vygon is a family company founded in 1962, based in Ecouen, in France's Greater Paris region. It is a mid-sized business employing over 2,700 staff worldwide. The turnover in 2024 was €417.9 million, with 81% of this derived from Vygon's international business.

www.vygon.com

Media and analyst contact

Andrew Lloyd & Associates

Celine Gonzalez – Lorraine Walters

US: +1 203 724 5950